SCHEMBL13610960

SCHEMBL13610960

Cc1cc2c(c(C(=O)NC[C@@H]3CCN(C(=O)OC(C)(C)C)CC3O)c1)OCCCO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
EED O75530 1/20 0.38
RBBP4 Q09028 1/20 0.38
SUZ12 Q15022 1/20 0.38
EZH2 Q15910 1/20 0.38
AEBP2 Q6ZN18 1/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 2/20 0.38
THRB P10828 1/20 0.38
USP30 Q70CQ3 2/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
ACKR3 P25106 1/20 0.37
LMNA P02545 1/20 0.37
GPR119 Q8TDV5 1/20 0.36
POLB P06746 1/20 0.35
UTS2R Q9UKP6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13603114 1.00 KDM4E (0.39) KDM4EPKMKMT2AMEN1EED
SCHEMBL13611212 1.00 KDM4E (0.39) KDM4EPKMKMT2AMEN1EED
SCHEMBL13315487 1.00 KDM4E (0.39) KDM4EPKMKMT2AMEN1EED
SCHEMBL13603119 1.00 KDM4E (0.39) KDM4EPKMKMT2AMEN1EED
SCHEMBL13603095 0.96 KDM4E (0.41) KDM4EPKMKMT2AMEN1EED
SCHEMBL13610975 0.91 KDM4E (0.38) KDM4EPKMKMT2AMEN1EED
SCHEMBL13603113 0.91 KDM4E (0.38) KDM4EPKMKMT2AMEN1EED
Water SCHEMBL5355004 0.90 UTS2R (0.40) KDM4EPKMKMT2AMEN1UTS2R
SCHEMBL13611210 0.90 DRD2 (0.40) KDM4EPKMTP53MAPTTHRB
SCHEMBL13603109 0.90 DRD2 (0.40) KDM4EPKMTP53MAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638535-B2 (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity JANSSEN PHARMACEUTICA N.V. (BE) 2009-12-29 US disclosed